Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 28100832.
- Also identified by DOI 10.1126/scitranslmed.aag2196 and PMC identifier 5260938.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy using CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs), engineered to express both herpes simplex virus type 1 thymidine kinase (HSV1-TK) and interleukin-13 (IL-13) zetakine chimeric antigen receptor (CAR), is a treatment strategy with considerable potential. To optimize this and related immunotherapies, it would be helpful to monitor CTL viability and trafficking to glioma cells. We show that noninvasive positron emission tomography (PET) imaging with 9-[4-[<sup>18</sup>F]fluoro-3-(hydroxymethyl)butyl]guanine ([<sup>18</sup>F]FHBG) can track HSV1-tk reporter gene expression present in CAR-engineered CTLs. [<sup>18</sup>F]FHBG imaging was safe and enabled the longitudinal imaging of T cells stably transfected with a PET reporter gene in patients. Further optimization of this imaging approach for monitoring in vivo cell trafficking should greatly benefit various cell-based therapies for cancer.
Medical subject headings
- Brain Neoplasms
- Genes, Reporter
- Glioma
- Immunotherapy
- Receptors, Antigen, T-Cell
- T-Lymphocytes, Cytotoxic